This anti-fibrotic effect, associated with the anti-inflammatory effect of MMP-9 inhibitor described in the DSS-colitis model by Marshall and colleagues using an alternative anti-MMP-9 antibody, AB-004631, supports the development of an anti-MMP-9 antibody in patients with penetrating CD. Here, MMP9 is linked to colitis.